{"blog": [], "keywords": [{"value": "Cephalon Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Federal Trade Commission", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Antitrust Laws and Competition Issues", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "5", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2015/05/29/business/teva-cephalon-provigil-ftc-settlement.html", "document_type": "article", "byline": {"person": [{"middlename": "R.", "firstname": "Rebecca", "role": "reported", "rank": 1, "lastname": "RUIZ", "organization": ""}, {"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 2}], "original": "By REBECCA R. RUIZ and KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/05/29/business/29FTC/29FTC-thumbWide.jpg", "legacy": {"wide": "images/2015/05/29/business/29FTC/29FTC-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/05/29/business/29FTC/29FTC-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/29/business/29FTC/29FTC-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2015/05/29/business/29FTC/29FTC-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/29/business/29FTC/29FTC-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1048", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The agency accused the company of illegally blocking generic competition to Provigil, a sleep-disorder drug.", "pub_date": "2015-05-29T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "F.T.C. Settles Suit With Drug Maker ", "main": "Teva Settles Cephalon Generics Case With F.T.C. for $1.2 Billion"}, "print_page": "1", "snippet": "The agency accused the company of illegally blocking generic competition to Provigil, a sleep-disorder drug.", "_id": "5567169438f0d86f0b8505d7", "slideshow_credits": null, "abstract": "Pharmaceutical company Cephalon will pay $1.2 billion to settle antitrust charges with Federal Trade Commission, largest settlement ever secured by FTC; company was charged with blocking generic competitors from entering market as patents expired on its lucrative sleep drug Provigil."}